Assessment of relative bioavailability of two presentations of moroctocog alfa (AF‐CC) in subjects with moderately severe or severe hemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|4|3|237-241

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.3, 2015-03, pp. : 237-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Memantine cost saving in moderately-severe to severe AD

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Memantine in Moderately-Severe-to-Severe Alzheimer's Disease: A Postmarketing Surveillance Study

By Clerici Francesca  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 321-332

Adis International

Access to resources Recommend Favorite

Drotrecogin-alfa relatively cost effective in severe sepsis

By  

Inpharma, Vol. 1, Iss. 1358, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Drotrecogin alfa improves organ function in severe sepsis

By  

Inpharma, Vol. 1, Iss. 1389, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Wyeth updates safety information for venlafaxine and moroctocog alfa

By  

Inpharma, Vol. 1, Iss. 1407, 2003-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite